Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181623 · ClinicalTrials.gov registry record · Phase 2
Recombinant Human Prolactin for Lactation Induction
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00181623: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00181623 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00181623, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and determine the effects of the hormone prolactin on lactation (breast milk production).
Primary Outcome
Treatment group
Interventions
- DRUG Recombinant Human Prolactin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2005-01 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
What the finished NCT00181623 record still lists
NCT00181623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Recombinant Human Prolactin is the first listed.
NCT00181623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00181623 about?
NCT00181623 is a clinical study titled "Recombinant Human Prolactin for Lactation Induction". The purpose of the study is to assess the safety and determine the effects of the hormone prolactin on lactation (breast milk production).
What is the current status of trial NCT00181623?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2005-01. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00181623?
The interventions under investigation include: Recombinant Human Prolactin (DRUG).
Who is sponsoring clinical trial NCT00181623?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00181623's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia